Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C (Q24200197)

title

Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C (English)

0 references

1 reference

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Goran Hauser

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Tahany Awad

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Davor Stimac

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

Mahasen Mabrouk

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

3

Kristian Thorlund

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

8 June 2020

publication date

28 February 2014

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

8 June 2020

page(s)

CD005642

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection

8 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Compare trial: updated data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

[Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Effect of hepatitis C virus and its treatment on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Ribavirin plus interferon versus interferon for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Apparently conclusive meta-analyses may be inconclusive--Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

SPIRIT 2013 statement: defining standard protocol items for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Hepatitis C virus genotypes and quasispecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Methods for combining randomized clinical trials: strengths and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Review article: pegylated interferons: chemical and clinical differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Hepatology may have problems with putative surrogate outcome measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Publication bias in clinical trials due to statistical significance or direction of trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Contradicted and initially stronger effects in highly cited clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Why most published research findings are false

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Publication of clinical trials supporting successful new drug applications: a literature analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pharmaceutical industry sponsorship and research outcome and quality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Industry sponsorship and research outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Interferon for interferon naive patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

State of the art in PEGylation: the great versatility achieved after forty years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Structural biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Systematic review: glucocorticosteroids for alcoholic hepatitis--a Cochrane Hepato-Biliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Recent advances in the molecular biology of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Arcsine test for publication bias in meta-analyses with binary outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

The history of the "natural history" of hepatitis C (1968-2009).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Estimating required information size by quantifying diversity in random-effects model meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005642.PUB3

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/14651858.CD005642.PUB3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24585451%20AND%20SRC:MED&resulttype=core&format=json

release_hg2aq42dvzcgdmozkc6t3v7y24

8 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hg2aq42dvzcgdmozkc6t3v7y24

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference